Cargando…
Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
BACKGROUND: In economic evaluations, survival is often extrapolated to smooth out the Kaplan-Meier estimate and because the available data (e.g., from randomized controlled trials) are often right censored. Validation of the accuracy of extrapolated results can depend on the length of follow-up and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226243/ https://www.ncbi.nlm.nih.gov/pubmed/37248477 http://dx.doi.org/10.1186/s12874-023-01952-2 |
_version_ | 1785050536865693696 |
---|---|
author | Bakker, LJ Thielen, FW Redekop, WK Groot, CA Uyl-de Blommestein, HM |
author_facet | Bakker, LJ Thielen, FW Redekop, WK Groot, CA Uyl-de Blommestein, HM |
author_sort | Bakker, LJ |
collection | PubMed |
description | BACKGROUND: In economic evaluations, survival is often extrapolated to smooth out the Kaplan-Meier estimate and because the available data (e.g., from randomized controlled trials) are often right censored. Validation of the accuracy of extrapolated results can depend on the length of follow-up and the assumptions made about the survival hazard. Here, we analyze the accuracy of different extrapolation techniques while varying the data cut-off to estimate long-term survival in newly diagnosed multiple myeloma (MM) patients. METHODS: Empirical data were available from a randomized controlled trial and a registry for MM patients treated with melphalan + prednisone, thalidomide, and bortezomib- based regimens. Standard parametric and spline models were fitted while artificially reducing follow-up by introducing database locks. The maximum follow-up for these locks varied from 3 to 13 years. Extrapolated (conditional) restricted mean survival time (RMST) was compared to the Kaplan-Meier RMST and models were selected according to statistical tests, and visual fit. RESULTS: For all treatments, the RMST error decreased when follow-up and the absolute number of events increased, and censoring decreased. The decline in RMST error was highest when maximum follow-up exceeded six years. However, even when censoring is low there can still be considerable deviations in the extrapolated RMST conditional on survival until extrapolation when compared to the KM-estimate. CONCLUSIONS: We demonstrate that both standard parametric and spline models could be worthy candidates when extrapolating survival for the populations examined. Nevertheless, researchers and decision makers should be wary of uncertainty in results even when censoring has decreased, and the number of events has increased. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-023-01952-2. |
format | Online Article Text |
id | pubmed-10226243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102262432023-05-30 Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma Bakker, LJ Thielen, FW Redekop, WK Groot, CA Uyl-de Blommestein, HM BMC Med Res Methodol Research BACKGROUND: In economic evaluations, survival is often extrapolated to smooth out the Kaplan-Meier estimate and because the available data (e.g., from randomized controlled trials) are often right censored. Validation of the accuracy of extrapolated results can depend on the length of follow-up and the assumptions made about the survival hazard. Here, we analyze the accuracy of different extrapolation techniques while varying the data cut-off to estimate long-term survival in newly diagnosed multiple myeloma (MM) patients. METHODS: Empirical data were available from a randomized controlled trial and a registry for MM patients treated with melphalan + prednisone, thalidomide, and bortezomib- based regimens. Standard parametric and spline models were fitted while artificially reducing follow-up by introducing database locks. The maximum follow-up for these locks varied from 3 to 13 years. Extrapolated (conditional) restricted mean survival time (RMST) was compared to the Kaplan-Meier RMST and models were selected according to statistical tests, and visual fit. RESULTS: For all treatments, the RMST error decreased when follow-up and the absolute number of events increased, and censoring decreased. The decline in RMST error was highest when maximum follow-up exceeded six years. However, even when censoring is low there can still be considerable deviations in the extrapolated RMST conditional on survival until extrapolation when compared to the KM-estimate. CONCLUSIONS: We demonstrate that both standard parametric and spline models could be worthy candidates when extrapolating survival for the populations examined. Nevertheless, researchers and decision makers should be wary of uncertainty in results even when censoring has decreased, and the number of events has increased. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-023-01952-2. BioMed Central 2023-05-29 /pmc/articles/PMC10226243/ /pubmed/37248477 http://dx.doi.org/10.1186/s12874-023-01952-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Bakker, LJ Thielen, FW Redekop, WK Groot, CA Uyl-de Blommestein, HM Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma |
title | Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma |
title_full | Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma |
title_fullStr | Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma |
title_full_unstemmed | Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma |
title_short | Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma |
title_sort | extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226243/ https://www.ncbi.nlm.nih.gov/pubmed/37248477 http://dx.doi.org/10.1186/s12874-023-01952-2 |
work_keys_str_mv | AT bakkerlj extrapolatingempiricallongtermsurvivaldatatheimpactofupdatedfollowupdataandparametricextrapolationmethodsonsurvivalestimatesinmultiplemyeloma AT thielenfw extrapolatingempiricallongtermsurvivaldatatheimpactofupdatedfollowupdataandparametricextrapolationmethodsonsurvivalestimatesinmultiplemyeloma AT redekopwk extrapolatingempiricallongtermsurvivaldatatheimpactofupdatedfollowupdataandparametricextrapolationmethodsonsurvivalestimatesinmultiplemyeloma AT grootcauylde extrapolatingempiricallongtermsurvivaldatatheimpactofupdatedfollowupdataandparametricextrapolationmethodsonsurvivalestimatesinmultiplemyeloma AT blommesteinhm extrapolatingempiricallongtermsurvivaldatatheimpactofupdatedfollowupdataandparametricextrapolationmethodsonsurvivalestimatesinmultiplemyeloma |